This Pill Could Reduce The Chance Of A Heart AttackJoseph Weber
The anticholesterol drug Mevacor was already generating nearly $1 billion in sales annually for Merck & Co. Then came word of a study that suggests strongly that the drug can curb a leading cause of heart attacks. The drug packs such a punch against the fatty arterial deposits known as plaque that the scientists conducting the study announced on Nov. 20 that they had canceled plans to extend their research for another year and a half.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Goldman Sachs Sees Four 2018 Fed Rate Hikes as U.S. Growth Gains
- Tesla Unveils ‘World’s Fastest Production Car’ and Electric Big Rig
- Norway Idea to Exit Oil Stocks Is ‘Shot Heard Around the World’
- Honda Recalls 800,000 Odyssey Minivans Linked to Injuries
- Why Are Critics Calling the $450 Million Painting Fake?